Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	12.35B +21.4%
Revenue (ttm)	401.12M -5.7%
Net Income	-183.13M
EPS	-1.38
Shares Out	157.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	503,472
Open	79.30
Previous Close	78.80
Day's Range	78.40 - 82.40
52-Week Range	61.60 - 93.70
Beta	0.60
Analysts	Strong Buy
Price Target	153.00 (+95.15%)
Earnings Date	Aug 12, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2025, Foresee Pharmaceuticals's revenue was 431.27 million, an increase of 3.01% compared to the previous year's 418.69 million. Losses were -883.15 million, -18.31% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error